The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin

Brain Research

Volumn 1305, Issue , 2009, Pages S2-

  Hammarberg, Anders ^a   Nylander, Ingrid ^b   Zhou, Qin ^b   Jayaram Lindström, Nitya ^a   Reid, Malcolm S ^c   Franck, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acamprosate; Alcohol dependence; Craving; HPA; Neuroendocrine; Treatment

Indexed keywords

EID: 71549117082     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.093     Document Type: Article

References (27)

1. Anton R.F., Moak D.H., and Latham P. The Obsessive-Compulsive Drinking Scale; a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin. Exp. Res. 19 (1995) 92-99
2. Besson J., Aeby F., Kasas A., Lehert P., and Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin. Exp. Res. 22 (1998) 573-579
3. Chick J., Howlett H., Morgan M.Y., and Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35 2 (2000) 176-187
4. Dahchour A., De Witte P., Bolo N., Nédélec J.F., Muzet M., Durbin P., and Macher J.P. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res. 82 2 (1998) 107-114
5. Drummond C.D. Theories of drug craving, ancient and modern. Addiction 96 1 (2001) 33-46
6. Hammarberg A., Jayaram-Lindström A., Beck O., Franck J., and Reid M.S. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: A randomized controlled trial. Psychopharm. (Berl) 205 1 (2009) 53-62
7. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach P., Kampf P., Stracke R., Baehr M., Naber D., and Wiedemann W. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psych. 60 (2003) 92-99
8. Kiefer F., Jahn H., Otte C., Nakovics H., and Wiedemann K. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. Neurosci. Lett. 404 1-2 (2006) 103-106 Epub 2006 Jun 19
9. Kiefer F., Jahn H., Otte C., Naber D., and Wiedemann K. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?. Biol. Psych. 60 (2006) 74-76
10. Love A., James D., and Willner P. A comparison of two alcohol craving questionnaires. Addiction 93 7 (1998) 1091-1102
11. Mann K., Lehert P., et al. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin. Exp. Res. 28 1 (2004) 51-63
12. Mason B.J., and Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev. Neurother. 7 11 (2007) 1465-1477
13. Morley K.C., Teesson M., Reid S.C., Sannibale C., Thomson C., Phung N., et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101 10 (2006) 1451-1462
14. Olive M.F., Nannini M.A., Ou C.J., Koenig H.N., and Hodge C.W. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur. J. Pharmacol. 437 1-2 (2002) 55-61
15. Ooteman W., Koeter M.W., Verheul R., Schippers G.M., and van den Brink W. Measuring craving: an attempt to connect subjective craving with cue reactivity. Alcohol Clin. Exp. Res. 30 1 (2006) 57-69
16. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Stern L., and Parot P. Double-blind randomised multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30 (1995) 239-247
17. Pelc I., Verbanck P., Le Bon O., Gavrilovic M., Lion K., and Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol dependent patients: a 90 days placebo- controlled dose finding study. Brit. J. Psych. 171 (1997) 73-77
18. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., Spanagel R., Zieglgänsberger W., and Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40 6 (2001) 746-749
19. Sass H., Soyka M., Mann K., and Zieglegansberger W. Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psych. 53 (1996) 673-680
20. Sobell L.C., and Sobell M.B. Timeline Follow Back. A technique for assessing self-reported alcohol consumption. In: Litten R., and Allen J. (Eds). Measuring Alcohol Consumption. Humana Press (1992) 41-72
21. Spanagel R., Hölter S.M., Allingham K., Landgraf R., and Zieglgänsberger W. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur. J. Pharmacol. 3 305 (1996) 39-44
22. Tempesta E., Janiri L., Bignamini A., Chabac S., and Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo controlled study. Alcohol Alcohol 35 (2000) 202-209
23. Verheul R., Lehert P., Geerlings P.J., Koeter M.W.J., and van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 178 (2005) 167-173
24. Zeise M.L., Kasparov S., Capogna M., and Zieglgänsberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 231 1 (1993) 47-52
25. Zalewska-Kaszubska J., Cwiek W., Dyr W., and Czarnecka E. Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neurosci. Lett. 388 1 (2005) 45-48
26. Zalewska-Kaszubska J., Górska D., Dyr W., and Czarnecka E. Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference. Neurosci. Lett. 431 3 (2008) 221-225 Epub 2007 Dec 4
27. Zimmermann U., Spring K., Koller G., Holsboer F., and Soyka. Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate. Pharmacopsychiatry 37 (2004) 98-102